Search
Cangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalAn advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor was approved by the FDA in June 2015 for intravenous application.
Clobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigational[A256868] Additionally, clobazam is believed to be a partial agonist to the GABA<sub>A</sub> receptor rather than non-selective full receptor agonists like 1,4-benzodiazepines, thus potentially explaining … [A256913] Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.
Categories: GABA-A Receptor AgonistsAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions … [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults.
Isopropyl myristate
go.drugbank.com/drugs/DB13966ApprovedIsopropyl myristate is a moisturizer with polar characteristics used in cosmetics and topical medical preparations to ameliorate the skin absorption. … [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].
Idoxuridine
go.drugbank.com/drugs/DB00249ApprovedWithdrawnAn analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque
Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled penMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnPenbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. … Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug.
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.
Radium Ra 223 dichloride
go.drugbank.com/drugs/DB08913ApprovedInvestigationalAs a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. … The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Synonyms: Radium chloride Ra-223, Radium (Ra-223) dichlorideProducts: Radium Ra 223 Dichloride